A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Conditions
Low Grade Serous Ovarian Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
HonorHealth, Phoenix, Arizona, United States
Contact: Principal Investigator (Lyndsay Willmott, MD)University of Arkansas, Little Rock, Arkansas, United States
Contact: Principal Investigator (Heather Williams, MD)UCLA Health, Los Angeles, California, United States
Contact: Principal Investigator (Ritu Salani, MD)UC Davis, Sacramento, California, United States
Contact: Principal Investigator (Hui Amy Chen, MD)University of California, San Francisco, San Francisco, California, United States
Contact: Principal Investigator (Jocelyn Chapman, MD)Yale University, New Haven, Connecticut, United States
Contact: Principal Investigator (Alessandro Santin, MD)Florida Cancer Specialists - South, Fort Myers, Florida, United States
Contact: Principal Investigator (Elizabeth Guancial, MD)Mount Sinai, Miami Beach, Florida, United States
Contact: Principal Investigator (Brian Slomovitz, MD)AdventHealth, Orlando, Florida, United States
Contact: Principal Investigator (Robert Holloway, MD)Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Hye Sook Chon, MD)Florida Cancer Specialists Research East, West Palm Beach, Florida, United States
Contact: Principal Investigator (Bradley Monk, MD)Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
Contact: Principal Investigator (Susan Modesitt, MD)NorthShore University HealthSystem, Evanston, Illinois, United States
Contact: Principal Investigator (Mary Tilley Jenkins-Vogel, MD)Louisiana State University, New Orleans, Louisiana, United States
Contact: Principal Investigator (Amelia Jernigan, MD)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Contact: Principal Investigator (Stephanie Gaillard, MD)Karmanos Cancer Center, Detroit, Michigan, United States
Contact: Principal Investigator (Robert Morris, MD)Minnesota Oncology Hematology, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Lauren Bollinger, MD)Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Premal Thaker, MD)Roswell Park Cancer Institute, Buffalo, New York, United States
Contact: Principal Investigator (Karen McLean, MD)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Rachel Grisham, MD)Atrium Health, Charlotte, North Carolina, United States
Contact: Principal Investigator (Erin Crane, MD)Cleveland Clinic Foundation, Cleveland, Ohio, United States
Contact: Principal Investigator (Peter Rose, MD)Ohio State, Hilliard, Ohio, United States
Contact: Principal Investigator (Christa Nagel, MD)University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States
Contact: Principal Investigator (Christina Washington, MD)Willamette Valley Cancer Institute, Eugene, Oregon, United States
Contact: Principal Investigator (Charles Anderson, MD)Northwest Cancer Specialists, Portland, Oregon, United States
Contact: Principal Investigator (Erin Salinas, MD)Asplundh Cancer Pavilion | Jefferson Health, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Mitchell Edelson, MD)Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Thomas Krivak, MD)Texas Oncology Central, Austin, Texas, United States
Contact: Principal Investigator (Lynn Knowles, MD)Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States
Contact: Principal Investigator (Noelle Cloven, MD)Houston Methodist, Houston, Texas, United States
Contact: Principal Investigator (Aparna Kamat, MD)MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Lauren Cobb, MD)Texas Oncology, San Antonio, Texas, United States
Contact: Principal Investigator (Antonio Santillan Gomez, MD)Texas Oncology, The Woodlands, Texas, United States
Contact: Principal Investigator (Christine Lee, MD)Texas Oncology, Tyler, Texas, United States
Contact: Principal Investigator (Anna M Priebe, MD)Intermountain Medical Center, Murray, Utah, United States
Contact: Principal Investigator (Ying Ning, MD)University of Virginia Health System, Charlottesville, Virginia, United States
Contact: Principal Investigator (Kari Ring, MD)Virginia Cancer Specialists, PC, Gainesville, Virginia, United States
Contact: Principal Investigator (Robert Marsh, MD)Prince of Wales Hospital, Randwick, New South Wales, Australia
Contact: Principal Investigator (Yeh Chen Lee, MD)Icon Cancer Centre Wesley, Auchenflower, Queensland, Australia
Contact: Principal Investigator (Jeffrey Goh, MD)Cancer Research South Australia, Adelaide, South Australia, Australia
Contact: Principal Investigator (Meena Okera, MD)Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Contact: Principal Investigator (Sumitra Ananda, MD)Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Contact: Principal Investigator (Tarek Meniawy, MD)UZA, Edegem, Belgium
Contact: Principal Investigator (Konstantinos Papadimitriou, MD)University Hospital Ghent, Ghent, Belgium
Contact: Principal Investigator (Hannelore Denys, MD)Princess Margaret Cancer Center, Toronto, Ontario, Canada
Contact: Principal Investigator (Amit Oza, MD)Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada
Contact: Principal Investigator (Diane Provencher, MD)McGill University Health Centre, Montreal, Quebec, Canada
Contact: Principal Investigator (Lucy Gilbert, MD)British of Columbia, Vancouver, Canada
Contact: Principal Investigator (Anna Tinker, MD)Aalborg U.H, Aalborg, Denmark
Contact: Principal Investigator (Charlotte A Haslund, MD)Centre Hospitalier de Besançon, Besançon, France
Contact: Principal Investigator (Laura Mansi, MD)Site Georges François Leclerc, Dijon, France
Contact: Principal Investigator (Jean-David Fumet, MD)Centre Oscar Lambret, Lille, France
Contact: Principal Investigator (Cyril Abdeddaim, MD)Centre Léon Bérard, Lyon, France
Contact: Principal Investigator (Isabelle Ray-Coquard, MD)Institut Curie, Paris, France
Agaplesion Markus Krankenhaus, Frankfurt am Main, Hesse, Germany
Contact: Principal Investigator (Marc Thill, MD)Charité - Universitätsmedizin Berlin, Berlin, Germany
Contact: Principal Investigator (Radoslav Chekerov, MD)Universitätsklinikum Carl Gustav Carus, Dresden, Germany
Contact: Principal Investigator (Pauline Wimberger, MD)Kliniken Essen-Mitte, Essen, Germany
Contact: Principal Investigator (Philipp Harter, MD)UMC Hamburg-Eppendorf, Hamburg, Germany
Contact: Principal Investigator (Barbara Schmalfeldt, MD)Universitätsklinikum Mannheim GmbH, Mannheim, Germany
Contact: Principal Investigator (Frederik Marmé, MD)Universitätsfrauenkinik Ulm, Ulm, Germany
Contact: Principal Investigator (Fabienne Schochter, MD)St. James's Hospital, Dublin, Ireland
Contact: Principal Investigator (Karen Cadoo, MD)Centro di Riferimento Oncologico (CRO), Aviano, Italy
Contact: Principal Investigator (Michelle Bartoletti, MD)Spedali Civili, Brescia, Italy
Contact: Principal Investigator (Germana Tognon, MD)AO Cannizzaro, Catania, Italy
Contact: Principal Investigator (Giuseppa Scandurra, MD)San Raffaele Hospital, Milan, Italy
Contact: Principal Investigator (Giorgia Mangili, MD)Humanitas San Pio X, Milan, Italy
Contact: Principal Investigator (Domenica Lorusso, MD)European Institute of Oncology (IEO), Milan, Italy
Contact: Principal Investigator (Nicoletta Columbo, MD)Istituto Nazionale dei Tumori, Milan, Italy
Contact: Study coordinator (Barbara Montesanto) · barbara.montesanto@istitutotumori.mi.it · 39 0223903619Contact: Principal Investigator (Mara Mantiero, MD)INT Napoli Hospital, Naples, Italy
Contact: Principal Investigator (Sabrina Cecere, MD)Istituto Oncologico Veneto (IOV), Padova, Italy
Contact: Principal Investigator (Valentina Guarneri, MD)IRCCS Gemelli, Roma, Italy
Contact: Principal Investigator (Vanda Salutari, MD)Istituti Fisioterapici Ospitalieri, Rome, Italy
Contact: Principal Investigator (Savarese Antonella, MD)S.C.D.U. Oncologia, Torino, Italy
Contact: Principal Investigator (Giorgio Valabrega, MD)The Mie University Hospital, Tsu, Mie-ken, Japan
Contact: Principal Investigator (Eiji Kondo, MD)Aichi Cancer Center Hospital, Aichi, Nagoya, Japan
Contact: Principal Investigator (Shiro Suzuki, MD)Tohoku University Hospital, Miyagi, Japan
Contact: Principal Investigator (Shogo Shigeta)Osaka Medical Center, Osaka, Japan
Contact: Principal Investigator (Satoe Fujiwara, MD)The Jikei University Hospital, Tokyo, Japan
Contact: Principal Investigator (Nozomu Yanaihara, MD)Netherlands Cancer Insitute, Amsterdam, Netherlands
Contact: Principal Investigator (Frans Opdam)Radboud UMC, Nijmegen, Netherlands
Contact: Principal Investigator (Nelleke Ottevanger, MD)Auckland City Hospital, Auckland, New Zealand
Contact: Principal Investigator (Michelle Wilson, MD)Białostockie Centrum Onkologii, Bialystok, Poland
Contact: Principal Investigator (Beata Maćkowiak-Matejczyk, MD)Gdański Uniwersytet Medyczny, Gdansk, Poland
Contact: Principal Investigator (Dagmara Klasa-Mazurkiewicz, MD)Siedleckie Centrum Onkologii, Siedlce, Poland
Contact: Principal Investigator (Bodnar Lubomir, MD)Seoul National University Bundang Hospital, Seongnam, South Korea
Contact: Principal Investigator (Kidong Kim, MD)Yonsei University Severance Hospital, Seoul, South Korea
Contact: Principal Investigator (Sang Wun Kim, MD)Asan Medical Center, Seoul, South Korea
Contact: Principal Investigator (Shin Wah Lee, MD)Gangnam Severance Hospital, Seoul, South Korea
Contact: Principal Investigator (Jae-Hoon Kim, MD)Samsung Medical Center, Seoul, South Korea
Contact: Principal Investigator (Chel Hun Choi, MD)Clínico Virgen de La Arrixaca, El Palmar, Murcia, Spain
Contact: Principal Investigator (Ana Puertes Boix, MD)H. de Donostia, Donostia / San Sebastian, San Sebastian, Spain
Contact: Study coordinator (Cristina Maria Churruca Galaz) · cristinamaria.churrucagalaz@osakidetza.eus · 34 943 32 81 51Contact: Principal Investigator (Cristina Maria Churruca Galaz, MD)H. Vall d´ Hebron, Barcelona, Spain
Contact: Principal Investigator (Ana Oaknin, MD)Hospital Universitario Reina Sofía, Córdoba, Spain
Contact: Principal Investigator (Maria Jesus Rubio, MD)H.U. Ramón y Cajal, Madrid, Spain
Contact: Principal Investigator (Alfonso Cortes Salgado, MD)Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Contact: Principal Investigator (Juan Cueva Bañuelos, MD)Hospital Clínico Universitario de Valencia, Valencia, Spain
Contact: Principal Investigator (Alejandro Perez Fidalgo, MD)Greater Glasgow and Clyde (GGC), Glasgow, Scotland, United Kingdom
Contact: Principal Investigator (Ros Glasspool, MD)Cambridge University Hospital, Cambridge, United Kingdom
Contact: Principal Investigator (Joo Ern Ang, MD)University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
Contact: Principal Investigator (Charlie Gourley, MD)Hope Cancer Trials Centre, Leicester, United Kingdom
Contact: Principal Investigator (Joey Wood, MD)University College London Hospitals NHS Foundation Trust, London, United Kingdom
Contact: Principal Investigator (Rowan Miller, MD)Royal Marsden Hospital, London, United Kingdom
Contact: Principal Investigator (Susana Banerjee, MD)The Christie NHS Foundation Trust, Manchester, United Kingdom
Contact: Principal Investigator (Andrew Clamp, MD)Royal Marsden Hospital, Sutton, United Kingdom
Contact: Principal Investigator (Susana Banerjee, MD)
Study leads
Rachel Grisham, MD
Principal Investigator
GOG Foundation
Susana Banerjee, MBBS, MA, PhD
Principal Investigator
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Craig Berman Verastem Medical Monitor
Study Director
RAMP301@verastem.com